Understanding the Relationship between Polycystic Ovarian Syndrome (PCOS) and Dyslipidemia

Chikadibia Fyneface Amadi *

Department of Medical Laboratory Science, Faculty of Allied Health Sciences, PAMO University of Medical Sciences, Rivers State, Nigeria.

Benjamin Nnamdi Okolonkwo

Department of Medical Laboratory Science, Faculty of Allied Health Sciences, PAMO University of Medical Sciences, Rivers State, Nigeria.

Melody Igochiyerum George-Oparati

Department of Medical Laboratory Science, Faculty of Allied Health Sciences, PAMO University of Medical Sciences, Rivers State, Nigeria.

Kingsley Kalawari Odiabara

Department of Medical Laboratory Services, Federal Ministry of Health, Abuja, Nigeria.

*Author to whom correspondence should be addressed.


Polycystic ovarian syndrome (PCOS) is a heterogenous disorder characterized by signs and symptom of androgen excess and ovarian dysfunction in the absence of other diagnosis, with a prevalence of ~6%-~20%. The aetiology of PCOS can either be unknown (primary) or originating from identifiable causes (secondary) like obesity, idiopathic hirsutism, epilepsy, androgen-secreting tumors etc. Weight gain especially around the stomach, missed, irregular or light menstruations, hyperandrogenism, infertility can serve as indicators for PCOS. This review is aimed at examining the relationship that exists between PCOS and dyslipidemia. With a prevalence report of about 70%, dyslipidemia, is related to PCOS, and its causes are multifactorial with many cases being undiagnosed due to different diagnostics criteria for PCOS. Studies revealed that women with PCOS showed increased levels of LDL-cholesterol, VLD Lipoprotein, ApoC-I, lipoprotein (a), decreased levels of HDL-cholesterol and ApoA-I while ApoB. Psychophysiology in dyslipidemia in PCOS include: obesity, hyperandrogenism. Insulin resistance. Diagnostic measures include: complete lipid profile test, pelvic ultrasound and transvaginal scan, hormone tests, glucose and insulin tolerance test, etc. There is no known cure of PCOS reported yet but there are different options on management which include lifestyle change, use of statin drugs if lifestyle modifications do not work, use of androgen inhibiting drugs and metformin might help. It is important and more advisable for the age range for PCOS testing to be reduced to accommodate females just entering puberty.

Keywords: Dyslipidemia, lipoprotein, PCOS

How to Cite

Amadi, C. F., Okolonkwo, B. N., George-Oparati, M. I., & Odiabara, K. K. (2023). Understanding the Relationship between Polycystic Ovarian Syndrome (PCOS) and Dyslipidemia. Asian Journal of Biochemistry, Genetics and Molecular Biology, 15(3), 1–11. https://doi.org/10.9734/ajbgmb/2023/v15i3333


Download data is not yet available.


Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE) & Androgen Excess and PCOS Society (AES). American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen excess and PCOS Society Disease State Clinical review: Guide to the best practices in the evaluation and treatment of Polycystic Ovary Syndrome--PART 1. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2015;21(11):1291–1300. Available:https://doi.org/10.4158/EP15748.DSC

Dunaif A, Fauser BC. Renaming PCOS--a two-state solution. The Journal of Clinical endocrinology and metabolism. 2013;98(11):4325–4328.

Available:https://doi.org/10.1210/jc.2013-2040 eMedicine. Polycystic Ovarian Syndrome. Available:https://emedicine.medscape.com/article/256806-overview

Eunice Kennedy Shriver National Institute of Child Health and Human Development. About Polycystic Ovarian Syndrome. https://www.nichd.nih.gov/health/topics/pcos/conditioninfo Eunice Kennedy Shriver National Institute of Child Health and Human Development."Is there a cure for PCOS?".


Dixon DL, Riche DM. Dyslipidemia. DiPiro JT, Yee GC, Posey L, Haines ST, Nolin TD, Ellingrod V(Eds.), Pharmacotherapy: A Pathophysiologic Approach. 2020;11e. McGraw Hill.


Oladapo-Akinfolarin TT, Oladapo M, Akinfolarin MCM, Amadi CF, Nwachukwu-Ibegbulem EO. The Effect of Parity on Atherogenic Indices in Normotensive Pregnant Women at 2nd Trimester. Healthcare Studies. 2023a;1(1):39-46.

Oladapo-Akinfolarin TT, Akinfolarin OM, Maduagwu MC, Amadi CF, Nwachukwu-Ibegbulem, EO. The Effect of Parity on Atherogenic Indices in Normotensive Pregnant Women at 2nd Trimester. Healthcare Studies. 2023b;1(1):39-46.

Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC medicine. 2010;8:41.

Available:https://doi.org/10.1186/1741- 7015-8-41

Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. The Journal of clinical endocrinology and metabolism. 2006;91(3):781–785.


Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human reproduction (Oxford, England). 2004;19(1):41–47. Available:https://doi.org/10.1093/humrep/deh098

Carmina E. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. Minerva ginecologica. 2004;56(1):1–6. Available:https://pubmed.ncbi.nlm.nih.gov/14973405/

Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best practice & research. Clinical obstetrics & gynaecology. 2004;18(5):671–683.


Khadilkar SS. Can Polycystic Ovarian Syndrome be cured? Unfolding the Concept of Secondary Polycystic Ovarian Syndrome! Journal of Obstetrics and Gynecology India. 2019;69:297–302.


Sati A, Desroziers E, Campbell RE. Microglia: sculptors of the polycystic ovary syndrome (PCOS)-like brain?. Reproduction. 2023;166(3):R51-61.

Indira IVF Fertility and IVF Centre. Type of PCOS – What are PCOS Symptoms and Treatment; 2022.


De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: anupdate. Reproductive biology and endocrinology: RB&E. 2016;14(1):38.


Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocrine reviews. 2015;36(5):487–525. Available:https://doi.org/10.1210/er.2015-1018

Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine. 2006;30(1):19–26. Available:https://doi.org/10.1385/ENDO:30:1:19

Cortet-Rudelli C, Dewailly D. "Diagnosis of Hyperandrogenism in Female Adolescents". Hyperandrogenism in Adolescent Girls. Armenian Health Network, Health.am; 2006.


Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta- analysis. Human reproduction update. 2014;20(5):748–758.


Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. Human reproduction update. 2010;16(4):347–363. Available:https://doi.org/10.1093/humupd/dmq001

Mayo Clinic. "Polycystic ovary syndrome (PCOS) - Symptoms and causes".


Barry JA, Kuczmierczyk AR, Hardiman PJ. Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis. Human reproduction (Oxford, England). 2011;26(9):2442–2451. Available:https://doi.org/10.1093/humrep/der197

Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertility and sterility. 2002;77(6):1095–1105. Available: https://doi.org/10.1016/s0015-0282(02)03111-4

de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: A systematic review and meta-analysis. Human reproduction update. 2011;17(4):495–500.


Goldenberg N, Glueck C. Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation. Minerva ginecologica. 2008;60(1):63–75. Available:https://pubmed.ncbi.nlm.nih.gov/18277353/

Boomsma CM, Fauser BC, Macklon NS. Pregnancy complications in women with polycystic ovary syndrome. Seminars in reproductive medicine. 2008;26(1):72–84. Available:https://doi.org/10.1055/s-2007-992927

Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nature reviews. Disease primers. 2017;3: 17093. Availabkle:https://doi.org/10.1038/nrdp.2017.93

Wild RA. Obesity, lipids, cardiovascular risk, and androgen excess. The American journal of medicine. 1995;98(1A):27S–32S. Available:https://doi.org/10.1016/s0002-9343(99)80056-4

Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Human reproduction (Oxford, England). 2003;18(11):2289–2293. Available:https://doi.org/10.1093/humrep/deg440

Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism: clinical and experimental. 2003; 52(7):908–915. Available: https://doi.org/10.1016/s0026-0495(03)00104-5

Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. The Journal of clinical endocrinology and metabolism. 2005;90(10):5711–5716.

Available: https://doi.org/10.1210/jc.2005-0011

Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism. 1985;61(5):946–951. Available:https://doi.org/10.1210/jcem-61-5-946

Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. The American Journal of Medicine. 2001;111(8):607–613.


Kim JJ, Chae SJ, Choi YM, Hwang KR, Song SH, Yoon SH, Kim SM, Ku SY, Kim SH, Kim JG, Moon SY. Atherogenic changes in low- density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome. Human reproduction (Oxford, England). 2013;28(5):1354–1360.


Dejager S, Pichard C, Giral P, Bruckert E, Federspield MC, Beucler I, Turpin G. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clinical endocrinology. 2001;54(4):455–462.

Available: https://doi.org/10.1046/j.1365-2265.2001.01245.x

Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertility and sterility. 2011;95(3):1073–9.e11. Available:https://doi.org/10.1016/j.fertnstert.2010.12.027

Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clinical chemistry. 2001;47(9):1579–1596.


Sidhwani S, Scoccia B, Sunghay S, Stephens-Archer CN, Mazzone T, Sam S. PCOS is associated with atherogenic changes in lipoprotein particle number and size independent of body weight. Clinical Endocrinology (Oxf); 2011.


Doi SA, Abbas JM, Parkinson L, Chakraborty J, Akanji AO. LDL species heterogeneity in the atherogenic dyslipidemia of polycystic ovary syndrome. American Journal of Clinical Pathology. 2008;129(5):802–810.


Berneis K, Rizzo M, Lazzarini V, Fruzzetti F, Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism. 2007;92(1):186–189. Available:https://doi.org/10.1210/jc.2006-1705

Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I, Spinas GA, Carmina E. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. International Journal of Clinical Practice. 2009;63(1):56– 62. Available:https://doi.org/10.1111/j.1742-1241.2008.01897.x

Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinas GA, Carmina E. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Human reproduction (Oxford, England). 2009;24(9):2286–2292. Available:https://doi.org/10.1093/humrep/dep121

Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertility and sterility. 2003;79(6):1358–1364.


Corbould A. Chronic testosterone treatment induces selective insulin resistance insubcutaneous adipocytes of women. The Journal of Endocrinology. 2007;192(3):585–594. https://doi.org/10.1677/joe.1.07070

Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. The American Journal of Medicine. 2001;111(4):261–269. Available:https://doi.org/10.1016/s0002-9343(01)00833-6

Luo X, Cai WY, Wu XK. Prevalence, Pattern and Predictors for Dyslipidemia of Chinese Women with Polycystic Ovary Syndrome. Frontiers in cardiovascular medicine. 2021;8:790454.


Lujan ME, Chizen DR, Pierson RA. Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. Journal of obstetrics and gynaecology Canada: JOGC = Journal d'obstetrique et gynecologie du Canada: JOGC. 2008; 30(8):671–679. Available:https://doi.org/10.1016/S1701-2163(16)32915-2

Sharquie KE, Al-Bayatti AA, Al-Ajeel AI, Al-Bahar AJ, Al-Nuaimy AA. Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome. Saudi medical journal. 2007;28(7):1039–1043.


Huang S, Qiao J, Li R, Wang L, Li M. Can serum apolipoprotein C-I demonstrate metabolic abnormality early in women with polycystic ovary syndrome? Fertility and sterility. 2010;94(1):205– 210.


Macpherson G. Black's Medical Dictionary (40 ed.). Lanham, MD: Scarecrow Press; 2002.

Dumont A, Robin G, Catteau-Jonard S, Dewailly D. Role of Anti-Müllerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review. Reproductive biology and endocrinology: RB&E. 2015;13:137. Available:https://doi.org/10.1186/s12958-015-0134-9

Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, Griesinger G, Kelsey TW, La Marca A, Lambalk C, Mason H, Nelson SM, Visser JA, Wallace WH, Anderson RA. The physiology and clinical utility of anti- Mullerian hormone in women. Human reproduction update. 2014;20(3):370–385.


Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Human reproduction update. 2014;20(5):688–701.


Muniyappa R, Madan R, Varghese RT. Assessing Insulin Sensitivity and Resistance in Humans. In K. R. Feingold (Eds.)., Endotext. MDText.com, Inc; 2021. Available:https://pubmed.ncbi.nlm.nih.gov/25905189/

Mortada R, Williams T. Metabolic Syndrome: Polycystic Ovary Syndrome. FP essentials. 2015;435:30–42.


Giallauria F, Palomba S, Vigorito C, Tafuri MG, Colao A, Lombardi G, Orio F. Androgens in polycystic ovary syndrome: the role of exercise and diet. Seminars in reproductive medicine. 2009;27(4):306–315.


Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. The Journal of Clinical Endocrinology and Metabolism. 2010;95(5):2038–2049.

Available: https://doi.org/10.1210/jc.2009-2724

Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double- blind placebo-controlled study. The Journal of Clinical Endocrinology and Metabolism. 2009; 94(1):103–108. Available:https://doi.org/10.1210/jc.2008-1750